Serum Platelet Factor 4 Is A Promising Therapeutic Response And Prognostic Marker In Patients With Newly Diagnosed Multiple Myeloma

Background: Angiogenesis is closely related with progression and prognosis of multiple myeloma (MM). Imbalance between pro- and anti-angiogenic factors leads to aberrant angiogenesis in MM. Platelet factor 4(PF4) is a potent antiangiogenic factor. It has been shown that PF4 and its p17-70 peptide can inhibit myeloma proliferation and angiogenesis both in vitro and in vivo. In addition, PF4 also directly induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in MM. We identified the peptide (m/z7763.24) with decreased relative intensity in newly diagnosed MM as PF4. Downregulation of PF4 in MM was revealed in several previous researches. However, the predictive analysis of serum PF4 level in newly diagnosed MM has not been well elucidated. Thus in the current study, we proposed to assess if serum PF4 could be a therapeutic response and prognostic marker in patients with newly diagnosed MM.